Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AbbVie Deutschland GmbH & Co. KG
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Study to Compare ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)
• To compare the safety and efficacy of ABT-494 versus placebo for the treatment of signs and symptoms of subjects with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT) Фаза 2, многоцентрово, открито изпитване-продължение (ОИП) с ABT-122 при пациенти с ревматоиден артрит, които са завършили предхождащото M12-963 фаза 2 рандомизирано контролирано изпитване (РКИ)
The primary objective is to assess the long-term safety and tolerability of ABT-122 in subjects with rheumatoid arthritis (RA) who have completed Study M12-963 Phase 2 RCT.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa Multicentrické klinické hodnocení bezpečnosti a účinnosti adalimumabu u subjektů se středně závažnou až závažnou Hidradenitis suppurativa
To evaluate the long-term safety, tolerability, and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS) who enter from a prior Phase 3 HS study.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Multicenter Study to Evaluate the Effects of Adalimumab on Quality of Life, Health Care Treatments and Health Care Costs in Subjects with Ulcerative Colitis
Assess the effect of adalimumab on QOL as measured by the Short Inflammatory Bowel Disease (SIBDQ), the utilization of health care resources and the costs of care for the UC subjects treated with adal...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast Cancer
To assess the progression-free survival of oral veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subj...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
The objective of this study is to evaluate the efficacy and safety of two doses of ABT-126 in subjects with mild-to-moderate Alzheimer's disease (AD) taking doses of AChEIs.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis. Estudio abierto y de un solo brazo de tratamiento para evaluar la eficacia y la seguridad de ABT 493/ABT 530 en adultos con infección crónica por el virus de la hepatitis C genotipos 1, 2, 4, 5 o 6 y cirrosis compensada
The primary objective of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) following 12 we...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
• To compare the safety and efficacy (signs and symptoms) of ABT-494 monotherapy versus MTX in MTX-inadequate response (MTX-IR) subjects with moderately to severely active rheumatoid arthritis (RA). •...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients with Erosive Hand Osteoarthritis
The primary objective is to evaluate the effect of ABT-981 on pain using the Australian/Canadian Osteoarthritis Hand Index (AUSCAN NR3.1) pain subdomain score, in subjects with erosive hand OA at Week...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 5 ans
Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies
The primary objectives of this study are to assess the efficacy by evaluating the percentage of subjects achieving a 12-week post-treatment sustained virologic failure response (SVR12) in each treatme...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next